Ticagrelor effectively and reversibly blocks murine platelet P2Y 12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 12, 2010, Pages 2385-2391

  Patil, Shankar B ^a   Jackman, Laura E ^a   Francis, Sheila E ^a   Judge, Heather M ^a   Nylander, Sven ^b   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

platelet receptor blockers; platelets; restenosis; thienopyridines; thrombosis

Indexed keywords

PADGEM PROTEIN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED STUDY; CREMASTER MUSCLE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

ADENOSINE; ANIMALS; BLEEDING TIME; BLOOD COAGULATION; BLOOD PLATELETS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS; TUNICA INTIMA;

EID: 78650419541     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.210732     Document Type: Article

References (32)

1. 2t receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
2. 12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:1810-1815.
3. 12 receptor. Curr Pharm Des. 2006;12:1255-1259.
4. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222-232.
5. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
6. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94:4156-4165.
7. 12 receptor in thrombosis. Curr Opin Hematol. 2003; 10:333-338.
8. 12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation. 2009;119:116-122.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
10. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
11. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: 494-502.
12. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
13. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787.
14. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: 3171-3175.
15. 12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J. 2006;27:1010-1012.
16. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.
17. 12 antagonists. Semin Thromb Hemost. 2005;31:195-204.
18. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851.
19. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856.
20. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, the PI. Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045-1057.
21. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET Study. Circulation. 2009;120:2577-2585.
22. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44-52. (Pubitemid 29035956)
23. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, the SI. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
24. Williams DO, Holubkov R, Yeh W, Bourassa MG, Al-Bassam M, Block PC, Coady P, Cohen H, Cowley M, Dorros G, Faxon D, Holmes DR, Jacobs A, Kelsey SF, King SB III, Myler R, Slater J, Stanek V, Vlachos HA, Detre KM. Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute registries. Circulation. 2000;102:2945-2951.
25. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha S-W, Clavijo LC, Kim S-W, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113: 1108-1113.
26. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-1385.
27. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc. 2002;288:2411-2420.
28. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, the T-TI. Pra-sugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
29. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
30. Chandrasekar B, Tanguay J-F. Platelets and restenosis. J Am Coll Cardiol. 2000;35:555-562.
31. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation. 1998;98:1616-1621.
32. 12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets. 2005;16:398-407.